Open AccessAn oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report
Author(s) -
Hiromichi Yamane,
Masahide Kinugawa,
Shigeki Umemura,
Yasuhiro Shiote,
Kenichiro Kudo,
Toshimitsu Suwaki,
Haruhito Kamei,
Nagio Takigawa,
Katsuyuki Kiura
Publication year - 2011
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v2.i7.299
Subject(s) - medicine , gemcitabine , interstitial lung disease , chest radiograph , chemotherapy , lung cancer , lung , gastroenterology , radiology
A 66-year-old Japanese man with pancreatic cancer received eleven courses of gemcitabine monotherapy. The tumor responded to gemcitabine until metastatic liver tumors progressed. Subsequently, he was treated with S-1, an oral fluoropyrimidine anticancer agent, as salvage chemotherapy. Forty-two days after initiating S-1, he presented with dyspnea and fever. Chest computed tomography showed diffuse interstitial lesions with thickening of the alveolar septa and ground glass opacity. Serum KL-6 level was elevated to 1,230 U/mL and he did not use any other drugs except insulin. Thus, the development of interstitial lung disease (ILD) was considered to be due to S-1. Arterial blood oxygen pressure was 49.6 Torr in spite of oxygen administration (5 L/min). Steroid therapy improved his symptoms and the interstitial shadows on chest radiograph. Although S-1-induced ILD has mostly been reported to be mild, clinicians should be aware that S-1 has the potential to cause fatal ILD.